<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231513</url>
  </required_header>
  <id_info>
    <org_study_id>E2814-A001-001</org_study_id>
    <nct_id>NCT04231513</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of single and&#xD;
      multiple intravenous infusions of E2814 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is comprised of two components: a single ascending dose (SAD) component and a&#xD;
      multiple ascending dose (MAD) component. The SAD component consists of 3 sequential cohorts&#xD;
      and in each cohort, 8 healthy participants are randomized (3:1) to receive a single dose of&#xD;
      E2814 or E2814-matched placebo. The MAD component of the study consists of 2 sequential&#xD;
      cohorts and in each cohort, 8 healthy participants are randomized (3:1) to receive E2814 or&#xD;
      E2814-matched placebo every 4 weeks (Q4W) on 3 occasions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">September 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAD, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD, Number of Participants With Clinically Significant Laboratory Values</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD, Number of Participants With Clinically Significant Vital Signs Values</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD, Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD, Number of Participants With TEAEs and SAEs</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD, Number of Participants With Clinically Significant Laboratory Values</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD, Number of Participants With Clinically Significant Vital Signs Values</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD, Number of Participants With Clinically Significant ECG Findings</measure>
    <time_frame>Up to 169 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD, Cmax Serum: Maximum Observed Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Tmax Serum: Time to Reach the Maximum Observed Concentration (Cmax) for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-24h) Serum: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 24 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-72h) Serum: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 72 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-inf) Serum: Area Under the Concentration-time Curve from Time 0 to Infinity for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, t½ Serum: Terminal Elimination Phase Half-life for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, CL Serum: Clearance for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Vz Serum: Volume of Distribution for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Serum anti-E2814 Antibody Concentration</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Cmax CSF: Maximum Observed Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 29 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Tmax CSF: Time to Reach the Maximum Observed Concentration (Cmax) for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 29 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-24h) CSF: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 24 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Cmax Plasma: Maximum Observed Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Tmax Plasma: Time to Reach the Maximum Observed Concentration (Cmax) for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-24h) Plasma: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 24 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-72h) Plasma: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 72 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, AUC (0-inf) Plasma: Area Under the Concentration-time Curve from Time 0 to Infinity for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, t½ Plasma: Terminal Elimination Phase Half-life for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, CL Plasma: Clearance for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Vz Plasma: Volume of Distribution for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD, Plasma anti-E2814 Antibody Concentration</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 113 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Cmax Serum: Maximum Observed Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Tmax Serum: Time to Reach the Maximum Observed Concentration (Cmax) for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-24h) Serum: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 24 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-72h) Serum: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 72 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-tau) Serum: Area Under the Concentration-time Curve From Zero Time to the end of the Dosing Interval for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, t½ Serum: Terminal Elimination Half-life for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, CL Serum: Clearance for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Vz Serum: Volume of Distribution for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Rac(Cmax) Serum: Ratio of Accumulation for Cmax for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Rac(AUC) Serum: Ratio of Accumulation for AUC for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Serum anti-E2814 Antibody Concentration</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, CSF Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 85 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Cmax Plasma: Maximum Observed Concentration for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Tmax Plasma: Time to Reach the Maximum Observed Concentration (Cmax) for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-24h) Plasma: Area Under the Concentration-time Curve From Time Zero to 24 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 24 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-72h) Plasma: Area Under the Concentration-time Curve From Time Zero to 72 Hour for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to 72 hours Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, AUC (0-tau) Plasma: Area Under the Concentration-time Curve From Zero Time to the end of the Dosing Interval for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, t½ Plasma: Terminal Elimination Half-life for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, CL Plasma: Clearance for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Vz Plasma: Volume of Distribution for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Rac(Cmax) Plasma: Ratio of Accumulation for Cmax for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Rac(AUC) Plasma: Ratio of Accumulation for AUC for E2814</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD, Plasma anti-E2814 Antibody Concentration</measure>
    <time_frame>Pre-dose (Day 1) and up to Day 169 Post Dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either E2814 or E2814-matched placebo, as an intravenous infusion, once, on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD, Cohort 3: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W up to Day 57 of the Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2814</intervention_name>
    <description>E2814, intravenous infusion.</description>
    <arm_group_label>MAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>MAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 3: E2814 or E2814-matched Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2814-matched placebo</intervention_name>
    <description>E2814-matched placebo, intravenous infusion.</description>
    <arm_group_label>MAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>MAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 1: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 2: E2814 or E2814-matched Placebo</arm_group_label>
    <arm_group_label>SAD, Cohort 3: E2814 or E2814-matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Nonsmoking, healthy participants.&#xD;
&#xD;
        Japanese participants must satisfy the following requirements:&#xD;
&#xD;
          1. Must have been born in Japan to Japanese parents and Japanese grandparents&#xD;
&#xD;
          2. Must have lived no more than 5 years outside of Japan&#xD;
&#xD;
          3. Must not have changed their life style or habits, including diet, while living outside&#xD;
             of Japan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant illness that requires medical treatment within 8 weeks or a&#xD;
             clinically significant infection that requires medical treatment within 4 weeks of&#xD;
             dosing&#xD;
&#xD;
          2. Females who are breastfeeding or pregnant at Screening or Baseline.&#xD;
&#xD;
          3. Females of childbearing potential who did not use a highly effective method of&#xD;
             contraception within 28 days before study entry, and do not agree to continue to use&#xD;
             contraception throughout the entire study period and for at least 28 days after study&#xD;
             drug discontinuation&#xD;
&#xD;
          4. Males who have not had a successful vasectomy (confirmed azoospermia) or they and&#xD;
             their female partners do not meet the criteria above (that is, not of childbearing&#xD;
             potential or practicing highly effective contraception throughout the study period and&#xD;
             for 5 times the half-life of the study drug plus 90 days after study drug&#xD;
             discontinuation). If the female partner is pregnant, then males who do not agree to&#xD;
             use latex, or synthetic condoms throughout the study period and for 90 days after&#xD;
             study drug discontinuation. No sperm donation is allowed during the study period and&#xD;
             for 5 times the half-life of the study drug plus 90 days after study drug&#xD;
             discontinuation.&#xD;
&#xD;
          5. Evidence of disease that may influence the outcome of the study within 4 weeks before&#xD;
             dosing; example, psychiatric disorders and disorders of the gastrointestinal tract,&#xD;
             liver, kidney, respiratory system, endocrine system, hematological system,&#xD;
             neurological system, or cardiovascular system, or participants who have a congenital&#xD;
             abnormality in metabolism&#xD;
&#xD;
          6. Any clinically abnormal symptom or organ impairment found by medical history, physical&#xD;
             examinations, vital signs, ECG finding, or laboratory test results that requires&#xD;
             medical treatment at Screening or Baseline&#xD;
&#xD;
          7. A prolonged QT (that is, corrected QT interval [QTc] Fridericia interval greater than&#xD;
             [&gt;] 450 milliseconds) demonstrated on ECG at Screening or Baseline. A history of risk&#xD;
             factors for torsade de pointes (example, heart failure, hypokalemia, family history of&#xD;
             long QT Syndrome)&#xD;
&#xD;
          8. Persistent systolic blood pressure (SBP) &gt;130 millimeters of mercury (mmHg) or&#xD;
             diastolic blood pressure (DBP) &gt;85 mmHg at Screening or Baseline. One repeat&#xD;
             measurement will be allowed&#xD;
&#xD;
          9. Heart rate less than 45 or more than 100 beats/minute at Screening or Baseline&#xD;
&#xD;
         10. Known history of clinically significant drug allergy at Screening or Baseline&#xD;
&#xD;
         11. Known history of food allergies or presently experiencing significant seasonal or&#xD;
             perennial allergy at Screening or Baseline&#xD;
&#xD;
         12. Any history of hypersensitivity reaction to a foreign protein, with clinical features&#xD;
             of Grades 2 to 4 as described in National Cancer Institute-Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) Version 5.0, immunoglobulin A (IgA) deficiency, or&#xD;
             significant autoimmune disease or disorder. Participants with hypersensitivity&#xD;
             reactions to foreign protein with clinical features limited to nasal or conjunctival&#xD;
             symptoms such as in allergic rhinitis do not need to be excluded.&#xD;
&#xD;
         13. Known to be human immunodeficiency virus (HIV) positive at Screening&#xD;
&#xD;
         14. Active or chronic (including asymptomatic) viral hepatitis (A, B or C) as demonstrated&#xD;
             by positive serology at Screening. For hepatitis B serology, this refers to positive&#xD;
             for hepatitis B core antibody (HBcAb, Immunoglobulin M [IgM] type) or hepatitis B&#xD;
             surface or core antigens (HBsAg, HBcAg). For hepatitis C serology, a positive result&#xD;
             for screening serological testing must be confirmed by qualitative hepatitis C virus&#xD;
             ribonucleic acid (RNA)&#xD;
&#xD;
         15. History of drug or alcohol dependency or abuse within the 2 years before Screening, or&#xD;
             those who have a positive urine drug test or breath (or urine) alcohol test at&#xD;
             Screening or Baseline&#xD;
&#xD;
         16. Intake of over-the-counter medications within 2 weeks before dosing&#xD;
&#xD;
         17. Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 30 days (or 5 half-lives, whichever is longer) preceding informed&#xD;
             consent&#xD;
&#xD;
         18. Exposure to any biologic drug within 90 days or at least 5 half-lives (whichever is&#xD;
             longer), or within 4 weeks for vaccines, before Screening&#xD;
&#xD;
         19. Engagement in strenuous exercise within 2 weeks before check-in (example, marathon&#xD;
             runners, weight lifters, etc.)&#xD;
&#xD;
         20. Any contraindication to continuous cerebrospinal fluid (CSF) sampling via indwelling&#xD;
             lumbar catheter or via lumbar puncture (LP)&#xD;
&#xD;
         21. Any history of or current blood clotting or bleeding disorder that is not under&#xD;
             adequate control, including a platelet count less than (&lt;) 50,000, international&#xD;
             normalized ratio (INR) &gt;1.3, or partial thromboplastin time (PTT) &gt; upper limit of&#xD;
             normal (ULN) at Screening or Baseline. Participants receiving anticoagulation therapy&#xD;
             or identified at risk for hemorrhage&#xD;
&#xD;
         22. Any lifetime suicidal behavior or psychiatric disease. Whenever possible, medical&#xD;
             records should be reviewed to confirm absence of history of psychiatric disease or use&#xD;
             of medications to treat psychiatric disease.&#xD;
&#xD;
         23. Any current or prior history of suicidal behavior or psychiatric disease identified by&#xD;
             the psychiatrist at the Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group/Parexel International</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E2814</keyword>
  <keyword>Healthy Participants</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Immunogenicity</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

